How Many Teva Pharmaceutical Industries Limited (NYSE:TEVA)’s Analysts Are Bearish?

September 16, 2018 - By James Douglas

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Logo

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Ratings Coverage

Among 12 analysts covering Teva Pharma (NYSE:TEVA), 3 have Buy rating, 1 Sell and 8 Hold. Therefore 25% are positive. Teva Pharma had 16 analyst reports since March 20, 2018 according to SRatingsIntel. Barclays Capital maintained the stock with “Equal-Weight” rating in Monday, August 6 report. The rating was maintained by Leerink Swann on Monday, June 11 with “Sell”. The firm earned “Market Perform” rating on Monday, June 18 by Wells Fargo. On Thursday, May 3 the stock rating was maintained by Wells Fargo with “Sell”. As per Tuesday, March 20, the company rating was maintained by Jefferies. As per Thursday, May 31, the company rating was maintained by Citigroup. Credit Suisse downgraded the shares of TEVA in report on Friday, September 7 to “Neutral” rating. Guggenheim maintained the stock with “Hold” rating in Thursday, May 24 report. As per Friday, August 3, the company rating was maintained by Morgan Stanley. The firm has “Hold” rating given on Sunday, March 25 by RBC Capital Markets. Below is a list of Teva Pharmaceutical Industries Limited (NYSE:TEVA) latest ratings and price target changes.

07/09/2018 Broker: Credit Suisse Old Rating: Outperform New Rating: Neutral Old Target: $25 New Target: $23 Downgrade
06/08/2018 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $20 New Target: $23 Maintain
03/08/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $19 New Target: $20 Maintain
16/07/2018 Broker: Cantor Fitzgerald Old Rating: Neutral New Rating: Neutral Old Target: $18 New Target: $25 Maintain
25/06/2018 Broker: Goldman Sachs Rating: Buy New Target: $28.0000 Upgrade
18/06/2018 Broker: Wells Fargo Old Rating: Underperform New Rating: Market Perform Upgrade
11/06/2018 Broker: Leerink Swann Rating: Sell New Target: $16.0000 Maintain
31/05/2018 Broker: Citigroup Old Rating: Buy New Rating: Buy Old Target: $24 New Target: $25 Maintain
24/05/2018 Broker: Guggenheim Rating: Hold Maintain
24/05/2018 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $13 New Target: $20 Maintain

The stock increased 2.88% or $0.64 during the last trading session, reaching $22.85. About 11.57 million shares traded or 13.04% up from the average. Teva Pharmaceutical Industries Limited (NYSE:TEVA) has risen 14.85% since September 16, 2017 and is uptrending. It has underperformed by 0.77% the S&P500.

Teva Pharmaceutical Industries Limited develops, makes, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. The company has market cap of $23.27 billion. It operates through two divisions, Generic Medicines and Specialty Medicines. It currently has negative earnings. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

More notable recent Teva Pharmaceutical Industries Limited (NYSE:TEVA) news were published by: Finance.Yahoo.com which released: “Why Teva’s Outlook Is Mixed” on August 23, 2018, also Seekingalpha.com with their article: “Teva +5% as migraine treatment wins FDA approval” published on September 14, 2018, Seekingalpha.com published: “Key events next week – healthcare” on September 14, 2018. More interesting news about Teva Pharmaceutical Industries Limited (NYSE:TEVA) were released by: Seekingalpha.com and their article: “Bausch Health resolves Xifaxan patent dispute with Actavis” published on September 12, 2018 as well as Seekingalpha.com‘s news article titled: “FDA OKs Teva’s opioid dependence med Cassipa” with publication date: September 07, 2018.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.